

BREAST	
<p>BREAST Adjuvant Supportive Care Location: Network NSH #: NSH1098 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Alliance A221102 - Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01573442?term=a221102&rank=1</p>
<p>BREAST Metastatic, 1st/2nd/3rd line, GpNMB +, TNBC Location: Network NSH #: C-132 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Celldex CDX-011-04 METRIC - A Randomized Multicenter Pivotal Study of CDX-011 (CRO11-vcMMAE) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study) Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01997333?term=cdx-011-04&rank=1</p>
<p>BREAST Metastatic, ER +, HER2 – Location: Network NSH #: C-242 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Alliance A011203 - A Randomized Phase II Trial of Tamoxifen Versus Z-Endoxifen HCL in Postmenopausal Women With Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02311933</p>
<p>BREAST Adjuvant , BRAC 1/2 + , HER2 –, ER/PR + or – Location: Network NSH #: C-197 Status: OPEN TO ACCRUAL</p>	<p>Protocol: NSABP B-55 - Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02032823?term=nsabp+b55&rank=1</p>
<p>BREAST Advanced or Metastatic, HER2 –, ER +, Post AI Location: Network NSH #: C-199 Status: OPEN TO ACCRUAL</p>	<p>Protocol: GO29058 SANDPIPER - A Phase III, Double-Blind, Placebo Controlled, Randomized Study of Taselisib Plus Fulvestrant versus Placebo Plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy Click for more information: https://clinicaltrials.gov/ct2/show/NCT02340221?term=sandpiper&rank=1</p>
<p>BREAST Post Neo-Adjuvant Triple Negative Basal-Like Location: Network NSH #: NSH1126 Status: ENROLLMENT ON HOLD</p>	<p>Protocol: ECOG EA1131 - A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Click for more information: https://clinicaltrials.gov/ct2/show/NCT02445391</p>

<p><u>BREAST</u> Adjuvant, Node + or High-Risk Node –, TNBC Location: Network NSH #: C-239 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>NRG-BR003 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02488967</p>
<p><u>BREAST</u> 1st line Metastatic TNBC Post Adjuvant Therapy Location: Network NSH #: C-247 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>DOMPE REP0114 - A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02370238?term=dompe+rep0114&rank=1</p>
<p>GLIOBLASTOMA</p>	
<p><u>GLIOBLASTOMA</u> Adjuvant Location: Network (Imaging @ NSH ONLY) NSH #: C-204 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>Alliance A071102 - A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02152982?term=a071102&rank=1</p>
<p>HEMATOLOGY</p>	
<p><u>HEMATOLOGY</u> Observational Bio-specimen Collection Location: Network NSH #: NSH1145 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>Study of Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02269592?term=NCT02269592&rank=1</p>
<p>LEUKEMIA</p>	
<p><u>LEUKEMIA</u> Relapsed or Refractory CLL with prior BTK or PI3K Location: GCS Research Offices NSH #: C-124 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>Gilead GS-US-339-0102 - A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies</i> Click for more information: https://www.clinicaltrials.gov/ct2/show/study/NCT01799889?term=gs-us-339-0102&rank=1</p>
<p>LUNG</p>	
<p><u>LUNG</u> Unresectable Stage IIIA or IIIB Non-Squamous NSCLC Location: Network (RT must be @ NSH ONLY) NSH #: NSH1121 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>RTOG1306 A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC)</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT01822496?term=rtog1306&rank=1</p>

<p>LUNG 2nd line + Metastatic Squamous Cell Carcinoma Sub-study B: Target P13k (GDC-0032) Sub-study C: Target CDK4/6 (Palbociclib) Sub-study D: Target FGFR (AZD4547) Sub-study I: Target (Nivolumab + Ipilimumab or Nivolumab)</p> <p>Location: Network NSH #: C-163 Status: OPEN TO ACCRUAL</p>	<p>Protocol: SWOG S1400 Lung-MAP - A Bio-marker Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02154490</p> <p>All eligible patients will be enrolled to protocol S1400 for biomarker profiling per Foundation Medicine. Based on those results, patients meeting detailed eligibility criteria will be assigned to one of the Sub-Studies.</p>
<p>LUNG Adjuvant ALK + or EGFR +</p> <p><i>All eligible patients will be enrolled to protocol A151216 in order to have tumor genotyping performed per central lab.</i></p> <p><i>If patient is EGFR +, they may be enrolled to protocol A081105.</i></p> <p><i>If patient is ALK +, they may be enrolled to protocol E4512.</i></p> <p>Location: Network NSH #: C-190, C-191, C-192 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) Click for more information: https://clinicaltrials.gov/ct2/show/NCT02194738?term=alchemist&rank=2</p> <p>Protocol: Alliance A081105 - Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) Click for more information: https://clinicaltrials.gov/ct2/show/NCT02193282?term=alchemist&rank=3</p> <p>Protocol: Alliance E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein Click for more information: https://clinicaltrials.gov/ct2/show/NCT02201992?term=alchemist&rank=4</p>
<p>LUNG 1st line Extensive Stage Small Cell Location: Network NSH #: C-198 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Oncomed 59R5-003 PINNACLE - A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) Click for more information: https://clinicaltrials.gov/ct2/show/NCT01859741?term=Pinnacle&rank=7</p>

<p>LUNG 1st line Stage IV Non-Squamous NSCLC Location: Network NSH #: C-246 Status: ENROLLMENT ON HOLD</p>	<p>Protocol: <i>IMpower - A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination with Carboplatin or Cisplatin + Pemetrexed Compared with Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02657434?term=NCT02657434&rank=1</p>
<p>LYMPHOMA</p>	
<p>LYMPHOMA 1st line Hodgkin Lymphoma ≥ 60 years old Location: GCS Research Offices NSH #: C-093 Status: ENROLLMENT ON HOLD</p>	<p>Protocol: <i>Seattle Genetics SGN 35-015 - A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above</i> Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT01716806</p>
<p>MELANOMA</p>	
<p>MELANOMA Unresectable Stage III or Metastatic Stage IV Location: Network NSH #: C-240 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>ECOG EA6141 Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma</i> Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02339571</p>
<p>MELANOMA Stage III or IV Resected NED Location: Network NSH #: C-188 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>ELIOS TLPLDC Vaccine - A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02301611?term=elios+tlpldc&rank=1</p>
<p>MELANOMA IIIA (N2a), IIIB, IIIC, or stage IV Resected Location: Network NSH #: C-248 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>SWOG 1404 - A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02506153?term=s1404&rank=1</p>
<p>MYELOMA</p>	
<p>MYELOMA 1st line Multiple Myeloma Location: Network NSH #: C-195 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>ECOG E1A11 Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT01863550?term=e1a11&rank=1</p>

PROSTATE	
<p>PROSTATE 1st line Metastatic Castration Resistant Location: Network NSH #: NSH1089 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Alliance A031201 - Phase III Trial of Enzalutamide (NSC# 766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer Click for more information: https://clinicaltrials.gov/ct2/show/NCT01949337?term=a031201&rank=1</p>
SARCOMA	
<p>SARCOMA Uterine Leiomyosarcoma Location: GCS Centerpointe NSH #: NSH1084 Status: OPEN TO ACCRUAL</p>	<p>Protocol: GOG0277 - A Phase III Randomized Trial of Gemcitabine (NSC# 613327) Plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) Versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma Click for more information: https://clinicaltrials.gov/ct2/show/NCT01533207?term=gog0277&rank=1</p>
<p>SARCOMA Soft Tissue Advanced Unresectable or Metastatic Location: GCS Centerpointe NSH #: C-231 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Eli Lilly I5B-MC-JGDJ - A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma (ANNOUNCE) Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02451943</p>
<p>SARCOMA Myxoid Liposarcoma Location: GCS Centerpointe NSH #: NSH1124 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Alliance A091202 - Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone vs. Placebo in Patients With Previously Treated, Unresectable Myxoid Liposarcoma Click for more information: https://www.clinicaltrials.gov/ct2/show/NCT02249949</p>
SOLID TUMOR	
<p>SOLID TUMOR & LYMPHOMA Genetic Marker Testing Location: Network NSH #: C-228 Status: ENROLLMENT ON HOLD</p>	<p>Protocol: ECOG EAY131 MATCH - Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas Click for more information: https://clinicaltrials.gov/ct2/show/NCT02465060?term=eay131&rank=1</p>
PHASE I	
<p>PHASE I TGA - Solid Tumor TGB – AML, CML, MM Location: GCS Centerpointe NSH #: NSH1097 Status: OPEN TO ACCRUAL</p>	<p>Protocol: Incyte INCB52793-101 - A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies Click for more information: https://clinicaltrials.gov/ct2/show/NCT02265510?term=incyte+101&rank=2</p>

<p><u>PHASE I</u> Extensive Stage SCLC Location: GCS Centerpointe NSH #: C-233 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>G1T28-03 - Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02514447?term=g1T28-03&rank=1</p>
<p><u>PHASE I</u> B-Cell Malignancies Location: GCS Centerpointe NSH #: NSH1115 Status: OPEN TO ACCRUAL</p>	<p>Protocol: <i>A Multi-center Phase I/Ib Study Evaluating the Efficacy and Safety of the Novel PI3k Delta Inhibitor TGR-1202 in Combination with Ibrutinib in Patients with Select B-Cell Malignancies</i> Click for more information: https://clinicaltrials.gov/ct2/show/NCT02268851?term=tgr-ib-105&rank=1</p>